ReviewNPJ vaccines2024
Recent progress on gene-deleted live-attenuated African swine fever virus vaccines.
Review in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 62 citations in OpenAlex.
- A dual-gene-deleted ASFV Lv17/WB/Rie1-ΔCD candidate administered orally to wild boar confers DIVA-compatible protection against virulent challenge.The veterinary quarterly · 2026Article
- Multiple directed mutagenesis reduces enzymatic activity and antibody recognition of the African Swine Fever Virus E2 ubiquitin-conjugating protein (ASFV-pI215L).Emerging microbes & infections · 2026Article
- The deletion of the EP402R and MGF505/360 genes attenuates a genotype I/II recombinant ASFV but fails to confer complete protection against homologous or genotype II challenge in pigs.Emerging microbes & infections · 2026Article
- Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence.Emerging microbes & infections · 2026Article
- Distinct cytotoxic cell subsets underlie protective and non-protective immunity to African swine fever virus.Emerging microbes & infections · 2026Article
- Live-attenuated African swine fever vaccine HLJ/18-7GD is safe in pregnant sows with no impact on reproductive performance or offspring health at a field farm.Emerging microbes & infections · 2026Article
- Vaccinology in the twenty-first century revisited.NPJ vaccines · 2026Article
- Article
- African swine fever virus pM448R protein promotes STUB1-mediated ubiquitin-proteasome degradation of IRF1 to attenuate type III interferon induction.Journal of virology · 2026Article
- Article
- Correlates of protection against African swine fever virus identified by a systems immunology approach.eLife · 2026Article
- Live-Attenuated Vaccines Against African Swine Fever: Strategies, Lessons, and Prospects.Biology · 2026Review
- Complete genome sequence of a Bangladesh-developed live-attenuated goatpox (GTPV) vaccine strain.Microbiology resource announcements · 2026Article
- Current Insights into the Epidemiology and Transmission Dynamics of African Swine Fever Virus and Future Control Perspectives.Pathogens (Basel, Switzerland) · 2026Review
- Adjuvant-induced macrophage activation compromises BA71ΔCD2-mediated protection against African swine fever virus.NPJ vaccines · 2026Article
- Article
- Virus-like and Virus Replicon Particles Targeting Multiple B-Cell Antigens Do Not Protect Against African Swine Fever Virus.Vaccines · 2026Article
- The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.Vaccines · 2026Review
- Recombinant vaccinia vectored ASFV vaccine enhances swine survival against genotype II challenge.NPJ vaccines · 2026Article
- African swine fever control in the context of endemic persistence.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
African Swine Fever (ASF) is a highly lethal viral disease in swine, with mortality rates approaching 100%. The disease has spread to many swine-producing countries, leading to significant economic losses and adversely impacting global food security. Extensive efforts have been directed toward developing effective ASF vaccines. Among the vaccinology approaches tested to date, live-attenuated virus (LAV) vaccines produced by rational deleting virulence genes from virulent African Swine Fever Virus (ASFV) strains have demonstrated promising safety and efficacy in experimental and field conditions. Many gene-deleted LAV vaccine candidates have been generated in recent years. The virulence genes targeted for deletion from the genome of virulent ASFV strains can be categorized into four groups: Genes implicated in viral genome replication and transcription, genes from the multigene family located at both 5' and 3' termini, genes participating in mediating hemadsorption and putative cellular attachment factors, and novel genes with no known functions. Some promising LAV vaccine candidates are generated by deleting a single viral virulence gene, whereas others are generated by simultaneously deleting multiple genes. This article summarizes the recent progress in developing and characterizing gene-deleted LAV vaccine candidates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.